Nikkei 225 · Precision optics (semiconductor lithography, nanoimprint)

Canon

Canon is a precision-optics conglomerate that earns over half its revenue from cameras and office equipment (Printing), but the real re-rating point hides in the 8%-of-sales Industrial unit — the call option on nanoimprint lithography (NIL), regarded as the one path to shrink chips without EUV (ASML). FY2025 consolidated sales of JPY 4,624.7bn (+2.5%) and OP of JPY 455.4bn make for modest top-line growth, but the profit gain is pulled by Imaging (+12.5%) and AI-related lithography while Printing (-1.1%) structurally shrinks. With the NIL it co-developed with Kioxia and DNP over a decade having shipped its first commercial tool (to TIE) in 2024, the question is whether a semiconductor-equipment option is embedded in a stock the market still prices as a declining camera/printer company.

7751.T Updated Jul 12, 2026 3 AI consumers

Per the valuechain.wiki graph, Canon is directly linked to 2 companies (1 supply, 1 revenue relationships) and reaches 6 companies within two hops; the links are backed by 10 dated sources, 3 of them primary filings (as of 2026-07-12).

Annual return · 2026-07-10'21+22.5%'22+11.1%'23+46.4%'24+27%'25-3.2%YTD-5.6%
Money inSemiconductor & FPD makers (i-line/KrF lithography)Texas Institute for Electronics (TIE) — first commercial NILKioxia (NIL co-development, NAND application)
CanonSales JPY 4,624.7bn
Money outOptical glass, aluminum, steel, chemicals (raw materials)Dai Nippon Printing (NIL masks/templates)Semiconductor chips (external procurement)

Financials & Segments

  • Total revenue · Sales JPY 4,624.7bn (+2.5%), OP JPY 455.4bn (OPM 9.8%), net profit JPY 332.1bn — a modest top line, with the profit gain pulled by Imaging and AI-driven lithography and dragged by Printing (FY2025 consolidated)
  • Customer concentration · The structure is 'a declining cash cow (Printing) funding a growth option (Industrial NIL).' The market prices Canon on camera/printer decline, but the real re-rating axis is whether the NIL it co-developed with Kioxia and DNP over a decade commercializes as a path to shrink that bypasses EUV. FY2025 OP JPY 455.4bn, OPM 9.8%.
  • Segments · Printing (53.9%) · Imaging (22.8%) · Medical (12.6%) · Industrial - lithography, NIL (7.8%)

Revenue from

  • Semiconductor & FPD makers (i-line/KrF lithography) High confidence
    At just 8% of sales, Industrial is where Canon's re-rating option sits — i-line/KrF scanners already earn cash at high share in mature IoT nodes, while FPD lithography leans on Korean panel makers. The real driver of FY2025's +2.7% was AI-related semiconductor investment, and against Nikon and ASML, Canon's hand is not leading-edge EUV but low-cost coverage of the mature and specialty layers beneath it.
    Confirms JA Canon Published Mar 25, 2026: Canon Integrated Report 2025 (FY ended Dec 2025)
    Confirms EN Canon Published Jan 29, 2026: Canon Inc. FY2025 Results (year ended Dec 31, 2025)
    Mentions EN SMBC Nikko Published Aug 19, 2024: SMBC Nikko upgrades Canon to Outperform, TP ¥5,500
    Confirms EN Canon Inc. (SEC EDGAR) Published Mar 30, 2023: Canon Inc. Form 20-F (FY2022)
  • Texas Institute for Electronics (TIE) — first commercial NIL High confidence
    The first commercial NIL reference — in 2024 Canon shipped an FPA-1200NZ2C to a Texas consortium backed by AMD, Intel, Micron and Applied Materials. What matters is less the revenue than the proof that a real semiconductor ecosystem will take and run it: with 14nm (5nm-node-class) patterning demonstrated, it signals NIL leaving the lab for a commercial trajectory.
    Confirms EN Canon Published Mar 1, 2025: Canon Annual Report 2024
    Confirms EN TrendForce Published Sep 30, 2024: Canon Delivers NIL System to TIE, Reportedly Capable of 2nm Chips
    Confirms EN Canon Published Sep 26, 2024: Canon delivers FPA-1200NZ2C NIL system to TIE
    Confirms EN Canon Published Oct 13, 2023: Canon launches the first nanoimprint lithography semiconductor system
  • Kioxia (NIL co-development, NAND application) Medium confidence
    NIL has no commercial future unless a major memory maker qualifies it on a production line — and Kioxia is that anchor customer. In the mutually dependent Canon (tool) / Kioxia (process) / DNP (mask) triangle, the NAND application does not exist without Kioxia. But it is still at tool-test/process-qualification stage, so what this relationship produces today is option value, not cash revenue.
    Confirms EN IEEE Spectrum Published Mar 1, 2024: Canon Delivers Nanoimprint Lithography to Compete With EUV
    Confirms EN Canon Published Oct 13, 2023: Nanoimprint Lithography (Canon Technology)

Pays to

  • Optical glass, aluminum, steel, chemicals (raw materials) High confidence
    Canon sources glass, aluminum, steel and chemicals globally while making key parts in-house to control external dependence — raw-material prices (e.g., crude) hit margins directly, but its degree of vertical integration acts as a cost-shock buffer versus peers.
    Confirms EN Canon Published Jan 29, 2026: Canon Inc. FY2025 Results (year ended Dec 31, 2025)
    Confirms EN Canon Inc. (SEC EDGAR) Published Mar 30, 2023: Canon Inc. Form 20-F (FY2022)
  • Dai Nippon Printing (NIL masks/templates) Medium confidence
    The upstream supplier of masks/templates (masters) in the NIL triangle — however precise Canon's tool, the node stalls if DNP's template shrink (targeting 1.4nm-class by 2027) does not keep pace. Canon's NIL roadmap is therefore chained to DNP's template roadmap: not a rivalry but a shared-fate dependency.
    Confirms EN IEEE Spectrum Published Mar 1, 2024: Canon Delivers Nanoimprint Lithography to Compete With EUV
    Confirms EN Canon Published Oct 13, 2023: Nanoimprint Lithography (Canon Technology)
  • Semiconductor chips (external procurement) Medium confidence
    Canon buys the chips that go into its cameras, printers and medical devices — a paradox for a company that itself sells semiconductor lithography yet depends on foundries for its own product chips; in a global chip shortage, higher input cost and delivery delays cut straight into sales.
    Mentions EN Canon Inc. (SEC EDGAR) Published Mar 30, 2023: Canon Inc. Form 20-F (FY2022)

Investments

  • Canon Medical Systems (formerly Toshiba Medical Systems) High confidence
    The 2016 acquisition of Toshiba Medical for ~JPY 665.5bn was a business investment that bought, whole, a non-imaging growth axis to offset the structural decline of cameras and printers — the result is FY2025 Medical sales of JPY 580.6bn, extended via Redlen (photon-counting CT) and Axis (network video) as Canon redeploys its optics/precision skills into healthcare and security.
    Confirms EN Canon Published Jan 29, 2026: Canon Inc. FY2025 Results (year ended Dec 31, 2025)
    Confirms EN Canon Inc. (SEC EDGAR) Published Mar 30, 2023: Canon Inc. Form 20-F (FY2022)

Value-chain ripple (2 tiers)

Following node-to-node links up to 2 tiers; each firm is shown once, at its nearest tier.

CompanyChain'21'22'23'24'25YTD
Everpure (formerly Pure Storage)lead2+44-17.8+33.3+72.3+9.1+18.4
NVIDIAlead2+125.5-50.3+239+171.2+38.9+13.3
Phison Electronicslead2+26.8-10.7+45.1-6.7+418.3-6
Kioxialead1····+1082.1+260.5
Canonnode+22.5+11.1+46.4+27-3.2-5.6
Dai Nippon Printingbenef1+56.5+13.9+42.6+8.5+22.5+15.3
Hoya Corporationbenef2+10.8-3+34.4+11.3+24.9-2.9

YTD as of 2026-07-10 · source: Yahoo Finance

Canon's thesis is 'a cash cow buying an option' — Printing, half of revenue, is in structural decline yet throws off cash, and that cash funds the Industrial NIL semiconductor-equipment option. In FY2025 (sales JPY 4,624.7bn, +2.5%; OP JPY 455.4bn) the profit gain came from Imaging (+12.5%) and AI-related lithography, while the market still prices camera/printer decline. The key variable is NIL's volume adoption: if a major memory maker in the Canon/Kioxia/DNP triangle puts it on an HVM line, Industrial re-rates from a 7.8% niche into a structural semiconductor-equipment story — though defect concerns keep the 'not yet' rebuttal alive. In the graph the ripple runs AI-chip capex → lithography demand → Canon (bypassing Nikon/ASML), with DNP's template shrink as the upstream roadmap bottleneck.

Analysis generated from returns as of 2026-07-10

← All companiesMarkdown · JSON

For information only, not investment advice. Content on this site is generated by AI from verified, cross-checked sources and may contain errors.

© 2026 Willow Investments, Inc.Company value-chain data · contact@willowinvt.com